News & Events
October 11, 2023 - October 15, 2023
IDWeek 2023Hosted in Boston, Mass. from October 11-15, IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP). CURE ID will have a booth to visit,...
October 6, 2023
Innovative Trial Design Approaches to Model Informed Drug Development in Rare and Neurological DiseasesAre you passionate about making a difference in the fields of neurology and rare diseases? Do you want to explore new methods that can revolutionize drug development in these critical areas? Join us for an enlightening webinar where we’ll delve into the latest advancements and strategies. Oct. 6, 2023 | 11 AM ET Gain an...
October 5, 2023
View Now — European Association of the Study of Diabetes Annual Meeting, C-Path T1D Consortium Presentation and ReceptionMembers of the C-Path team joined EASD 2023 for groundbreaking discussions on Immunotherapy and Beta Cell Preservation in Type 1 Diabetes, taking us from clinical trials to clinical practice. Click here to view the recordings.
September 28, 2023 - September 29, 2023
Complex In Vitro Model: Qualification Framework Public Workshop\Critical Path Institute’s Predictive Safety Testing Consortium hosted a public workshop on September 28-29, 2023 in Bethesda, Maryland with stakeholders from the U.S. Food and Drug Administration, academia, model developers, and the pharmaceutical industry to improve complex in vitro model (CIVM) development. Attendees discussed model standards and features that will enable the qualification of liver...
September 11, 2023 - September 13, 2023
View Now: 2023 Rare and Orphan Disease Conference presented by C-PathPatients, providers, researchers, clinicians, biopharmaceutical companies, regulatory reviewers and scientists will leave this 2.5-day conference with an understanding of: C-Path’s Rare and Orphan Disease Program’s current and future impact on drug development in rare diseases The Critical Path for Rare Neurodegenerative Diseases (CP-RND) initiative’s first year impact and highlights How RDCA-DAP has been...